← GSK plc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
ASSETS
Trade And Other Receivables $6.0b $6.0b $6.4b $7.2b $7.0b $7.9b $7.1b $7.4b $6.8b $7.5b
Goodwill $6.0b $5.7b $5.8b $10.6b $10.6b $10.6b $7.0b $6.8b $7.0b $7.0b
Intangible Assets Other Than Goodwill $18.8b $17.6b $17.2b $31.0b $29.8b $30.1b $14.3b $14.8b $15.5b $16.7b
Additional Financial Items
Decrease Increase Through Tax On Share-Based Payment Transactions ($7.0m) $4.0m ($2.0m) ($19.0m) $4.0m ($11.0m) $8.0m ($7.0m) ($4.0m) ($31.0m)
Deferred Tax Assets $4.4b $3.8b $3.9b $4.1b $4.3b $5.2b $5.7b $6.0b $6.8b $6.5b
Issued Capital $1.3b $1.3b $1.3b $1.3b $1.3b $1.3b $1.3b $1.3b $1.3b $1.3b
Trade And Other Current Payables $12.0b $21.0b $14.0b $14.9b $15.8b $17.6b $16.3b $15.8b $15.3b $15.4b
Trade And Other Current Receivables $6.0b $6.0b $6.4b $7.2b $7.0b $7.9b $7.1b $7.4b $6.8b $7.5b
Unused Tax Losses For Which No Deferred Tax Asset Recognised — — $24.0m $15.0m $18.0m $5.0m — — — —
Total Assets $59.1b $56.4b $58.1b $79.7b $80.4b $79.1b $60.1b $59.0b $59.5b $61.1b
LIABILITIES AND EQUITY
Deferred Tax Liabilities $1.9b $1.4b $1.2b $3.8b $3.6b $3.6b $289.0m $311.0m $382.0m $291.0m
Deferred Tax Liability Asset $2.4b $2.4b ($2.7b) $286.0m $687.0m $1.7b $5.4b ($5.7b) ($6.4b) ($6.2b)
Increase Decrease Through Business Combinations Deferred Tax Liability Asset — — — ($2.8b) ($25.0m) ($1.0m) ($495.0m) ($144.0m) ($190.0m) $321.0m
Increase Decrease Through Net Exchange Differences Deferred Tax Liability Asset — ($65.0m) $84.0m $103.0m ($55.0m) ($36.0m) ($102.0m) ($127.0m) ($30.0m) $79.0m
Total Liabilities $54.1b $52.9b $54.4b $61.3b $59.6b $57.8b $50.0b $46.2b $46.4b $45.2b
Noncontrolling Interests $3.8b $3.6b ($688.0m) $7.0b $6.2b $6.3b ($502.0m) ($552.0m) ($585.0m) ($421.0m)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.